While others have described a dose-dependent effect of pharmacologic MGMT inhibition on radiosensitivity (19), the prevailing consensus does not support a significant influence of MGMT promoter region methylation on the response to radiotherapy in glioblastoma (20–22). The gene discussed is MGMT; the disease is glioblastoma.